Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.

NCT05763875 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

350

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia

Interventions

DRUG: Inclisiran
DRUG: Ezetimibe
DRUG: Matching Placebo for Inclisiran
DRUG: Matching Placebo for Ezetimibe

Sponsor

Novartis Pharmaceuticals